Recent Investment Analysts’ Ratings Updates for Biogen (BIIB)

Biogen (NASDAQ: BIIB) has recently received a number of price target changes and ratings updates:

• 12/18/2025 – Biogen had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a “market perform” rating on the stock.
• 12/15/2025 – Biogen had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Biogen had its price target raised by analysts at Morgan Stanley from $149.00 to $156.00. They now have an “equal weight” rating on the stock.
• 12/10/2025 – Biogen had its “reduce” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $143.00 price target on the stock, down previously from $144.00.
• 12/10/2025 – Biogen was downgraded by analysts at Hsbc Global Res from a “hold” rating to a “moderate sell” rating.
• 12/10/2025 – Biogen had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an “equal weight” rating on the stock.
• 12/8/2025 – Biogen had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Biogen had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Biogen had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a “buy” rating on the stock.
• 11/25/2025 – Biogen was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 11/21/2025 – Biogen had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock, up previously from $118.00.
• 11/19/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/9/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/7/2025 – Biogen was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 11/6/2025 – Biogen was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $202.00 price target on the stock, up previously from $144.00.
• 11/3/2025 – Biogen was given a new $157.00 price target on by analysts at Tudor Pickering.
• 11/3/2025 – Biogen had its price target raised by analysts at Mizuho from $169.00 to $177.00. They now have an “outperform” rating on the stock.
• 11/3/2025 – Biogen had its price target raised by analysts at Sanford C. Bernstein from $155.00 to $157.00. They now have a “market perform” rating on the stock.
• 11/1/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 10/31/2025 – Biogen had its price target raised by analysts at Wells Fargo & Company from $140.00 to $155.00.
• 10/31/2025 – Biogen had its price target raised by analysts at Wedbush from $135.00 to $143.00. They now have a “neutral” rating on the stock.
• 10/31/2025 – Biogen had its price target raised by analysts at Guggenheim from $165.00 to $185.00.
• 10/31/2025 – Biogen had its price target raised by analysts at BMO Capital Markets from $128.00 to $150.00.
• 10/31/2025 – Biogen had its price target lowered by analysts at Royal Bank Of Canada from $217.00 to $210.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – Biogen had its price target lowered by analysts at Robert W. Baird from $255.00 to $250.00.
• 10/24/2025 – Biogen was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.